🟢 Tiziana Life Sciences is trading 5.8% up today after BTIG initiated coverage with a Buy rating

Tiziana Life Sciences is trading 5.8% up at $1.03 after BTIG initiated coverage with a Buy rating on September 3, 2026.

• BTIG set a $7.00 price target, highlighting intranasal foralumab and upcoming INFORM-MS data as potential catalysts.
• The move appears company-specific, despite broader U.S. indexes trading lower on September 4, 2026.
• BTIG’s initiation and target were reported by multiple financial outlets.